Last $1.21 USD
Change Today -0.0099 / -0.81%
Volume 107.6K
UPI On Other Exchanges
As of 2:00 PM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

uroplasty inc (UPI) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/3/14 - $4.15
52 Week Low
01/26/15 - $1.05
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for UROPLASTY INC (UPI)

Related News

No related news articles were found.

uroplasty inc (UPI) Related Businessweek News

No Related Businessweek News Found

uroplasty inc (UPI) Details

Uroplasty, Inc., a medical device company, develops, manufactures, and markets products for the treatment of voiding dysfunctions primarily in the United States. It principally offers Urgent PC Neuromodulation system, a minimally-invasive, neuromodulation system that delivers percutaneous tibial nerve stimulation for office-based treatment of overactive bladder and the associated symptoms of urinary urgency, urinary frequency, and urge incontinence. The company also provides Macroplastique implants, an injectable and urethral bulking agent for the treatment of adult female stress urinary incontinence due to intrinsic sphincter deficiency, as well as for the treatment of male stress incontinence, fecal incontinence, vocal cord rehabilitation, and vesicoureteral reflux. In addition, it offers Macroplastique products for treatment of vesicoureteral reflux; Urgent PC System for the treatment of fecal incontinence; PTQ Implants, which provides a minimally-invasive, soft-textured permanent implant for treatment of fecal incontinence; and VOX Implants, a silicone elastomer bulking material for vocal cord rehabilitation applications, as well as distributes wound care products. The company sells its products primarily to urologists, urogynecologists, and gynecologists through a direct sales organization in the United Kingdom, the Netherlands, Switzerland, and the Nordic countries, as well as through distributors in other markets. Uroplasty, Inc. was incorporated in 1992 and is headquartered in Minnetonka, Minnesota.

113 Employees
Last Reported Date: 01/27/15
Founded in 1992

uroplasty inc (UPI) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $589.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $212.7K
Vice President of Corporate Development
Total Annual Compensation: $195.1K
Senior Vice President of Global Sales and Mar...
Total Annual Compensation: $332.3K
Compensation as of Fiscal Year 2014.

uroplasty inc (UPI) Key Developments

Vision-Sciences's Merger With Uroplasty Will Lead To Future Acquisitions

Howard Zauberman, President and Chief Executive Officer of Vision-Sciences Inc. (NasdaqCM:VSCI) said during the earnings call for the third quarter of 2015 that the combined company, Cogentix Medical, as a result of Vision-Sciences's merger with Uroplasty, Inc. (NasdaqCM:UPI) will have greater resources to invest in future acquisitions, access capital markets and evaluate other growth opportunities. The combined company will be a strong platform from which to grow both organically and through additional strategic acquisitions.

Uroplasty, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014; Provides Revenue Guidance for the Fourth Quarter of Fiscal 2015 and Fiscal 2015

Uroplasty, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, the company reported net sales of USD 6,666,905 compared to USD 6,398,675 a year ago. Operating loss was USD 2,083,873 compared to USD 654,671 a year ago. Loss before income taxes was USD 2,084,400 compared to USD 651,341 a year ago. Net loss was USD 2,105,338 compared to USD 670,832 a year ago. Basic and diluted net loss per common share was USD 0.10 compared to USD 0.03 a year ago. The impact of changes in foreign currency exchange rates negatively impacted revenue by approximately USD 0.1 million. Excluding noncash charges for share based compensation and depreciation and amortization expense, the non GAAP operating loss was USD 1.5 million (USD 0.7 million excluding merger related costs) in the third quarter of fiscal 2015, compared with a USD 0.3 million non-GAAP operating loss in the year ago period. Excluding merger related costs, the non-GAAP loss per diluted share in the third quarter of fiscal 2015 was USD 0.06. For the nine months, the company reported net sales of USD 19,506,164 compared to USD 18,216,391 a year ago. Operating loss was USD 5,323,171 compared to USD 4,171,607 a year ago. Loss before income taxes was USD 5,320,132 compared to USD 4,157,571 a year ago. Net loss was USD 5,375,917 compared to USD 4,207,604 a year ago. Basic and diluted net loss per common share was USD 0.25 compared to USD 0.20 a year ago. Net cash used in operating activities were USD 3,196,457 compared to USD 2,264,543 a year ago. Purchases of property, plant and equipment was USD 206,498 compared to USD 221,769 a year ago. For the fourth quarter of fiscal 2015, the company currently expects Urgent PC sales to grow approximately 15% over the same quarter of the prior fiscal year and currently expected global Macroplastique sales to be approximately USD 2.0 million, which is consistent with the revenue generated from this product line over the prior four quarters. Total fiscal year 2015 revenue is now expected to be in a range from USD 26.5 million to USD 26.8 million.

Uroplasty, Inc. to Report Q3, 2015 Results on Jan 22, 2015

Uroplasty, Inc. announced that they will report Q3, 2015 results at 4:30 PM, US Eastern Standard Time on Jan 22, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UPI:US $1.21 USD -0.0099

UPI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bacterin International Holdings Inc $3.67 USD +0.0801
Cardica Inc $0.60 USD -0.0323
Stereotaxis Inc $2.43 USD +0.06
Urologix Inc $0.08 USD 0.00
Vision Sciences Inc/DE $0.48 USD -0.0178
View Industry Companies

Industry Analysis


Industry Average

Valuation UPI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.0x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UROPLASTY INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at